News Preview
Moderna Stock Selloff: Why positive cancer vaccine results failed to lift shares
Moderna shares plunged after detailed cancer vaccine trial results triggered profit-taking, despite reducing melanoma recurrence risk by 42%. Investors are weighing commercial prospects, regulatory timelines, and future oncology opportunities.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.